Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Survival under treatment

From: Osteopontin splice variants are differential predictors of breast cancer treatment responses

  Years of survival
Treatment Mean std n
hormone no (all subgroups) 6.48 3.96 54
hormone yes (all subgroups) 7.44 4.35 64
hormone alone 9.89 2.00 18
hormone and chemo 6.63 4.38 16
hormone and radiation 5.10 4.63 10
hormone, chemo, radiation 7.10 4.84 21
chemo no (all subgroups) 8.30 3.79 30
chemo yes (all subgroups) 6.57 4.22 89
chemo alone 7.92 4.57 13
chemo and hormone 6.63 4.38 16
chemo and radiation 5.82 3.66 39
chemo, hormone, radiation 7.10 4.84 21
chemo (CMF 6 courses every 28 days) 6.27 4.36 55
chemo (AC 4 courses every 21 days, CMF 6 courses every 28 days) 7.06 4.00 34
radiation no (all subgroups) 8.23 3.90 47
radiation yes (all subgroups) 6.21 4.17 72
radiotherapy alone 10.00 1.41 2
radiation and hormone 5.10 4.63 10
radiation and chemo 5.82 3.66 39
radiation, chemo, hormone 7.10 4.84 21
  1. Shown are mean survival times in years (mean), standard deviation (std), and number of cases (n) consecutive to the various combinations of treatment. When censored for 13-year survivors (who may be alive beyond 13 years), the mean survival of patients under hormone treatment is 6.423 years with standard error 0.5274, compared to survival under no hormone treatment of 7.262 years and standard error 0.5077